Abstract
FosA, a glutathione S-transferase that inactivates fosfomycin, has been reported as the cause of enzymatic resistance to fosfomycin. We show that multiple lineages of FosA-producing extended spectrum β-lactamase Escherichia coli have circulated in France since 2012, potentially reducing the efficacy of fosfomycin in treating infections with antimicrobial drug-resistant gram-negative bacilli.
Keywords:
ESBL; Escherichia coli; France; acquired resistance; antimicrobial resistance; bacteria; enteric infectious; extended spectrum β-lactamase; food safety; foodborne infections; fosA; fosfomycin; phosphonoformiate.
MeSH terms
-
Anti-Bacterial Agents / metabolism
-
Anti-Bacterial Agents / pharmacology*
-
Drug Resistance, Multiple, Bacterial / drug effects
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli / genetics
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / drug therapy
-
Escherichia coli Infections / epidemiology*
-
Escherichia coli Infections / microbiology
-
Escherichia coli Proteins / genetics*
-
Escherichia coli Proteins / metabolism
-
Foscarnet / pharmacology
-
Fosfomycin / metabolism
-
Fosfomycin / pharmacology*
-
France / epidemiology
-
Gene Expression
-
Humans
-
Isoenzymes / genetics
-
Isoenzymes / metabolism
-
Microbial Sensitivity Tests
-
Plasmids / chemistry
-
Plasmids / metabolism
-
Prevalence
-
beta-Lactamases / genetics*
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Escherichia coli Proteins
-
FosA(3) protein, E coli
-
Isoenzymes
-
Fosfomycin
-
Foscarnet
-
beta-Lactamases